|Security||STQN / Strategic Acquisitions, Inc.|
|Common Shares Outstanding||2,515,000 shares (as of 2018-03-31)|
Institutional Stock Ownership and Shareholders()
Strategic Acquisitions, Inc. (OTC:STQN) has 0 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
Largest shareholders include
Strategic Acquisitions, Inc. (OTC:STQN) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Related News Stories
Key players and manufacturers are increasingly focusing on expansion and acquisition, for the purpose of enhancing their functional effectiveness as well as product portfolio. Apart from this, joint ventures and strategic collaborations are likely to improve the production sales of electric and hydraulic wellhead drive for the onshore application in the forthcoming years. (1-0)
PayPal Holdings, Inc. (PYPL - Free Report) is set to report second-quarter 2018 results on Jul 25. The company topped the Zacks Consensus Estimate in the trailing four quarters, delivering an average positive earnings surprise of 6.35%. In the last reported quarter, PayPal’s earnings of 57 cents per share grew 29.5% on a year-over-year basis and 3.6% sequentially. The figure also surpassed the Zacks Consensus Estimate by 3 cents. (11-0)
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Nike (NKE), Morgan Stanley (MS) and FedEx (FDX). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. (39-0)
AMETEK is a global manufacturer of electronic instruments and electromechanical devices with around $4.5 billion in annual revenues. (31-0)
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), NVIDIA (NVDA) and Danaher (DHR). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. (164-0)
as of ET